Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors A Prospective Multicenter Stratified Randomized Trial

被引:27
|
作者
Deng, Xiangbing [1 ]
Liu, Ping [2 ]
Jiang, Dan [3 ]
Wei, Mingtian [1 ]
Wang, Xin [4 ]
Yang, Xuyang [1 ]
Zhang, Yuanchuan [5 ]
Wu, Bing [6 ]
Liu, Yanjun [5 ]
Qiu, Meng [4 ]
Zhuang, Hua [7 ]
Zhou, Zongguang [1 ]
Li, Yunfeng [2 ]
Xu, Feng [4 ]
Wang, Ziqiang [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[2] Kunming Med Univ, Affiliated Hosp 3, Colorectal Canc Clin Res Ctr, Kunming, Yunnan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Canc Ctr, Chengdu, Peoples R China
[5] Third Peoples Hosp Chengdu, Dept Gen Surg, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Ultrasound, Chengdu, Peoples R China
关键词
local recurrence; rectal cancer; risk stratification; short-course radiotherapy; total moserectal excision;
D O I
10.1097/SLA.0000000000003649
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: The aim of this study was to compare stage II/III rectal cancers with or without high-risk factors, and evaluate the effect of neoadjuvant radiotherapy (NRT) in these 2 cohorts. Background: NRT is often used in stage II/III rectal cancers to improve local control, while not affecting overall survival. However, good-quality surgery without NRT may also achieve good local control in selected patients. Methods: According to risk-stratification criteria and clinical staging, consecutive eligible participants of stage II/III rectal cancer were preoperatively classified into patients with (high-risk) or without (low-risk) high-risk factors. Both groups were respectively randomized to receive either short-course radiotherapy (SCRT) + total mesorectal excision (TME) or TME alone, forming the following 4 groups: high-risk patients with (HiR) or without (HiS) radiation, and low-risk patients with (LoR) or without (LoS) radiation. The primary endpoint was local recurrence. The secondary endpoints included overall survival, disease-free survival, distant recurrence, quality of surgery, and safety (NCT01437514). Results: In total, 401 patients were analyzed. With a median 54 months' follow-up, low-risk patients obtained better 3-year cumulative incidence of local recurrence (2.2% vs 11.0%, P = 0.006), overall survival rate (86.9%vs 76.5%, P = 0.002), disease-free survival rate (87.0% vs 67.9%, P < 0.001), and cumulative incidence of distant recurrence (12.5% vs 29.4%, P < 0.001) than high-risk patients. With regard to 3-year cumulative incidence of local recurrence, no differences were observed between the LoR and LoS groups (1.2% vs 3.0%, P = 0.983) or the HiR and HiS groups (12.9% vs 8.9%, P = 0.483). Conclusions and Relevance: Stratification of stage II/III rectal cancers according to risk factors to more precise subclassifications may result in noteworthy differences in survivals and local pelvic control. An extremely low cumulative incidence of local recurrence and survivals in low-risk patients can be achieved with upfront good quality of surgery alone. This trial, owing to the insufficient power, could not prove the noninferiority of surgery alone, but suggest a discriminative use of NRT according to clinical risk stratification in stage II/III rectal cancer.
引用
收藏
页码:1060 / 1069
页数:10
相关论文
共 50 条
  • [1] Neoadjuvant radiotherapy vs. surgery alone for stage II/III mid-low rectal cancer with or without high risk factors: A multicenter randomized trial.
    Wang, Ziqiang
    Deng, Xiangbing
    Liu, Ping
    Wang, Xin
    Jiang, Dan
    Wei, Mingtian
    Zhang, Yuanchuan
    Wu, Qingbin
    He, Wanbin
    Yang, Xuyang
    Yang, Tinghan
    Wang, Meng
    Wu, Bing
    Liu, Yanjun
    Meng, Wenjian
    Qiu, Meng
    Zhuang, Hua
    Li, Yunfeng
    Xu, Feng
    Zhou, Zongguang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Effect of neoadjuvant chemotherapy and early chemotherapeutic low/intermediated-risk mid-low stage II/III rectal cancer: A prospective, open-label, single-arm, phase II trial.
    Deng, Xiangbing
    Bi, Liang
    Wu, Qingbin
    He, Du
    Gou, Hongfeng
    Wu, Bing
    Yu, Yongyang
    Meng, Wenjian
    Meng, Qiu
    Wang, Ziqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Preoperative Radiotherapy versus postoperative Radiotherapy after neoadjuvant Chemotherapy ("NeoRad") in High-risk Breast Cancer: a prospective, randomized, international multicenter Phase III Study
    Matuschek, Christiane
    Jazmati, Danny
    Krug, David
    Corradini, Stefanie
    Fehm, Tanja
    Ruckhaeberle, Eugen
    Kuehn, Thorsten
    Stickeler, Elmar
    Nestle-Kraemling, Carolin
    Holtschmidt, Johannes
    Nekljudova, Valentina
    Loibl, Sibylle
    Budach, Wilfried
    ONKOLOGIE, 2024, 30 (09): : 840 - 844
  • [4] Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial
    Fan, Wen-Hua
    Wang, Fu-Long
    Lu, Zhen-Hai
    Pan, Zhi-Zhong
    Li, Li-Ren
    Gao, Yuan-Hong
    Chen, Gong
    Wu, Xiao-Jun
    Ding, Pei-Rong
    Zeng, Zhi-Fan
    Wan, De-Sen
    CHINESE JOURNAL OF CANCER, 2015, 34
  • [5] Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
    Feng, Yan-Ru
    Zhu, Yuan
    Liu, Lu-Ying
    Wang, Wei-Hu
    Wang, Shu-Lian
    Song, Yong-Wen
    Wang, Xin
    Tang, Yuan
    Liu, Yue-Ping
    Ren, Hua
    Fang, Hui
    Zhang, Shi-Ping
    Liu, Xin-Fan
    Yu, Zi-Hao
    Li, Ye-Xiong
    Jin, Jing
    ONCOTARGET, 2016, 7 (18) : 25576 - 25584
  • [6] Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial)
    Kiyotaka Okuno
    Toru Aoyama
    Koji Oba
    Noboru Yokoyama
    Nobuhisa Matsuhashi
    Katsuyuki Kunieda
    Yoji Nishimura
    Hiroki Akamatsu
    Takaya Kobatake
    Satoshi Morita
    Takaki Yoshikawa
    Junichi Sakamoto
    Shigetoyo Saji
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 65 - 71
  • [7] Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial
    Lahousen, M
    Haas, J
    Pickel, H
    Hackl, A
    Kurz, C
    Ogris, H
    Stummvoll, W
    Winter, R
    GYNECOLOGIC ONCOLOGY, 1999, 73 (02) : 196 - 201
  • [8] Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: A randomized multicenter phase 3 trial
    Jin, J.
    Feng, Y. R.
    Li, Y. X.
    Zhu, Y.
    Liu, L. Y.
    Wang, W. H.
    Wang, S. L.
    Song, Y. W.
    Wang, X.
    Tang, Y.
    Liu, Y. P.
    Ren, H.
    Fang, H.
    Zhang, S. P.
    Liu, X. F.
    Yu, Z. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S350 - S350
  • [9] Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)
    Dewdney, Alice
    Cunningham, David
    Tabernero, Josep
    Capdevila, Jaume
    Glimelius, Bengt
    Cervantes, Andres
    Tait, Diana
    Brown, Gina
    Wotherspoon, Andrew
    de Castro, David Gonzalez
    Chua, Yu Jo
    Wong, Rachel
    Barbachano, Yolanda
    Oates, Jacqueline
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1620 - 1627
  • [10] Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study
    Kamiya, T.
    Uehara, K.
    Nakayama, G.
    Ishigure, K.
    Kobayashi, S.
    Hiramatsu, K.
    Nakayama, H.
    Yamashita, K.
    Sakamoto, E.
    Tojima, Y.
    Kawai, S.
    Kodera, Y.
    Nagino, M.
    EJSO, 2016, 42 (06): : 829 - 835